转移因子胶囊对自身免疫性甲状腺病的免疫调节作用

The immunomodulatory effect of transfer factor capsule on AITD

目的自身免疫性甲状腺病(AITD)患者体内存在高滴度甲状腺自身抗体(TAA):抗甲状腺过氧化物酶抗体(TPOAb)和甲状腺球蛋白抗体(TgAb),参与甲状腺滤泡细胞的自身免疫紊乱过程。本研究探讨免疫调节剂转移因子胶囊是否可降低AITD患者TAA的浓度。方法 62例AITD患者分为A组33例,按甲状腺激素水平给予抗甲状腺药物(ATDs)或左旋甲状腺素(L-T4)治疗,甲功正常者仅观察;B组29例,在上述治疗基础上加转移因子胶囊口服。治疗前及治疗3个月后检测TAA滴度,进行组间及组内比较分析。结果组内治疗前后比较:与同组治疗前相比,A组治疗后TPOAb及TgAb滴度均无明显下降(P值均>0.05);B组治疗后TPOAb及TgAb滴度均显著下降(P值均<0.05)。组间比较:治疗前两组间TPOAb及TgAb滴度均无显著差异(P值均>0.05);治疗后两组的TPOAb及TgAb滴度均呈下降趋势,下降幅度B组显著大于A组(P<0.01);治疗后两组间TPOAb及TgAb滴度均有显著差异(P值均<0.05)。结论 AITD患者体内存在高滴度的TPOAb及TgAb,免疫调节剂转移因子胶囊可明显降低AITD患者的TPOAb及TgAb滴度。

Objective Patients with AITD have high titer thyroid auto antibody（TAA）.Thyroperoxidase antibodies（TPOAb） and antithyroglobulin antibodies（TgAb） are involved in the autoimmune disorder of parafollicular cells of thyroid gland.The study aims to find out whether the immunomodulatory transfer factor capsule can lower the density of TAA when treated to patients with AITD.Methods Sixty-two cases of AITD patients were divided into two groups,namely Group A and Group B.There were 33 patients in Group A and they are treated with ATDs or L-T4 in terms of their thyroid hormone level.Those with normal level were just observed.There were 29 patients in Group B.They were given the same treatment but transfer factor capsules are also required to take orally.The titer level of TAA was compared between and within groups.Results Intra-group comparison before and after treatment： there was no statistical significance in the decrease of TPOAb and TgAb titer（P0.05） after treatment.Comparison between groups： Before treatment,there was no significant difference in TPOAb and TgAb titer level between the two groups（P0.05）.After treatment,the TPOAb and TgAb titer levels in both groups were on the decrease.The descent range in Group B was superior to that in Group A which has a statistical meaning.The TPOAb and TgAb titer levels had significant difference in both groups after treatment（P0.05）.Conclusion Patients with AITD have high titer TAA.The immunomodulatory transfer factor capsule can significantly lower the density of TAA.